Biomarkers of Glioblastoma Multiforme Current update

Abstract

Glioblastoma multiforme (G.B.M.) represents one of the commonest intracranial tumor associated with very poor prognosis. Despite recent advances in genomics and microneurosurgical techniques, chemotherapy regimens, radiation technology but despite of these mortality and morbidity still remains unacceptable very high. Various markers are utilized to stratify into different category in a desperate attempt to find out suitable therapeutic regimen to promote improved neurological outcome. Authors briefly reviews various biomarkers and utility in management of GBM.